Systemic lupus erythematosus and the gut microbiome: To look forward is to look within - A systematic review and narrative synthesis.

Autoimmun Rev

Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; Unidade de Imunologia Clínica, ULS Santo António, Largo Prof. Abel Salazar, 4099-001, Porto, Portugal.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease shaped by complex interactions involving genetic and environmental factors. Among these, the gut microbiome is emerging as potentially modulating immune responses and influencing disease susceptibility, progression, and activity.

Objectives: To synthesize current evidence on gut microbiome changes in adult SLE patients, framed along the clinical pathway - from diagnosis to treatment - to help bridge bench and bedside for microbiome-informed SLE care and research.

Methods: A systematic search identified primary research studies examining gut microbiota in adult SLE patients. Studies were reviewed in a stepwise manner by independent investigators. Findings were synthesized narratively, emphasizing human data.

Results: SLE patients exhibit gut microbiome dysbiosis, with reduced microbial richness and altered bacterial taxa. A lower Firmicutes/Bacteroidetes ratio is frequently observed. Enrichment of specific taxa, such as Enterococcus, Lactobacillus, and Ruminococcus gnavus, is reported. Dysbiosis correlates with increased gut permeability, immune activation, and autoreactivity. Clinical associations include disease activity, flares, nephritis, and other manifestations. SLE treatments, such as hydroxychloroquine and corticosteroids, influence the microbiome. Emerging interventions such as dietary modulation and fecal microbiota transplantation show promise in early studies. However, considerable heterogeneity exists across studies in terms of patient characteristics, methodology, and taxa-level findings.

Conclusions: The gut microbiome has multifaceted associations with SLE pathogenesis, disease activity, and therapeutic response. Translation will require standardized methods, functional validation, longitudinal follow-up, and clinical integration. While uncertainties remain, the gut microbiome is increasingly relevant, and clinicians caring for patients with SLE should be aware of its emerging implications.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2025.103921DOI Listing

Publication Analysis

Top Keywords

gut microbiome
24
sle patients
12
systemic lupus
8
lupus erythematosus
8
gut
8
sle
8
microbiome emerging
8
adult sle
8
disease activity
8
microbiome
7

Similar Publications

Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.

View Article and Find Full Text PDF

This study investigated the association between parameters derived from bioelectrical impedance spectroscopy (BIS) and arterial stiffness, as measured using carotid-femoral pulse wave velocity (cfPWV) and brachial-ankle pulse wave velocity (baPWV) pulse wave velocities. Data from 292 Japanese adults were analyzed. BIS was used to assess the phase angle (PhA), extracellular water to intracellular water ratio (ECW/ICW), and body cell mass-to-free fat mass ratio (BCM/FFM).

View Article and Find Full Text PDF

Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.

Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.

View Article and Find Full Text PDF

Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.

View Article and Find Full Text PDF

Gut microbiome and mitochondrial crosstalk in Schizophrenia, a mental disability: Emerging mechanisms and therapeutic targets.

Neurosci Biobehav Rev

September 2025

Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur, 603203, Chengalpattu District, Tamil Nadu, India. Electronic address:

Gut-mitochondria is an emerging paradigm in understanding the pathophysiology of complex neuropsychiatric disorders such as Schizophrenia (SCZ). This bidirectional communication network connects the gastrointestinal microbiota with mitochondrial function and brain health, offering novel insights into disease onset and progression. SCZ, characterized by hallucinations, delusions, cognitive impairments, and social withdrawal, has traditionally been attributed to genetic and neurochemical imbalances.

View Article and Find Full Text PDF